We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Embolization, a technique used to block blood flow to specific areas of the body, is widely employed in the treatment of various conditions, including tumors, aneurysms, and arteriovenous malformations. Among the many materials explored for embolization, hydrogels have emerged as a promising candidate due to their unique properties, such as biocompatibility, tunable mechanical strength, and controlled degradation. At STEMart, we offer specialized development services to support the design, testing, and optimization of hydrogel-based embolic agents. Our end-to-end solutions are designed to accelerate the development of innovative and effective embolic agents, ensuring they meet the highest standards of safety, efficacy, and regulatory compliance.
Fig.1 Schematic illustration of hydrogel‐based embolic agents.1
STEMart provides a comprehensive suite of services designed to streamline the development of next-generation hydrogel-based embolic agents. Our expertise spans the entire development pipeline, from material synthesis and characterization to preclinical and regulatory support. We offer in-depth in vitro and in vivo testing, leveraging advanced imaging and analytical techniques to evaluate material performance and biocompatibility.
STEMart offers a wide range of hydrogel materials for embolic agent development, including natural polymers and synthetic polymers such as polyethylene glycol (PEG). Our team can customize formulations to meet specific clinical requirements, including adjusting gelation time, mechanical properties, and biodegradability. Furthermore, we facilitate real-time procedural visualization by incorporating imaging agents, such as radiopaque materials, into our hydrogel formulations.
Our capabilities encompass the fabrication of hydrogel-based embolic agents in diverse forms, such as microspheres, injectable gels, or pre-formed implants. We also offer scalable production of prototypes, ensuring efficient progression from initial design to rigorous testing and evaluation.
Our in vitro models simulate blood flow and vascular conditions to assess gelation, adhesion, and occlusion efficacy. For in vivo evaluation, we use animal models to study the embolic effects, biocompatibility, and long-term stability of the agents. We have extensive experience in conducting rigorous testing to ensure that our hydrogel-based embolic agents perform consistently and safely under a variety of conditions.
STEMart is a trusted partner in developing advanced medical materials and technologies. Our team of scientists, engineers, and regulatory experts is dedicated to delivering innovative solutions that meet the highest standards of quality and safety. By choosing STEMart for your hydrogel-based embolic agent development needs, you benefit from:
Contact us today to learn more about our hydrogel-based embolic agent development service and how we can support your research and development efforts.
Reference
We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy